These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 30800562)

  • 21. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
    Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
    Diabetes Ther; 2020 Apr; 11(4):951-964. PubMed ID: 32166619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.
    Seino Y; Inagaki N; Haneda M; Kaku K; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    J Diabetes Investig; 2015 Jul; 6(4):443-53. PubMed ID: 26221523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
    Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
    Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
    Gantz I; Okamoto T; Ito Y; Sato A; Okuyama K; O'Neill EA; Engel SS; Lai E;
    Diabetes Ther; 2017 Aug; 8(4):793-810. PubMed ID: 28589493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.
    Hirose T; Suzuki M; Tsumiyama I
    Diabetes Ther; 2015 Dec; 6(4):559-571. PubMed ID: 26620049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
    Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
    Sheu WH; Gantz I; Chen M; Suryawanshi S; Mirza A; Goldstein BJ; Kaufman KD; Engel SS
    Diabetes Care; 2015 Nov; 38(11):2106-14. PubMed ID: 26310692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial.
    Sawano F; Kamei N; Miyahara M; Kobuke K; Nakanishi S; Nagano C; Nojima H; Maeda S; Watanabe H; Kishimoto R; Yamashita M; Hamaoka A; Mukai K; Tsuboi T; Mochizuki H; Nakashima R; Sakashita Y; Morishita H; Kitamura T
    Diabetol Int; 2021 Oct; 12(4):364-378. PubMed ID: 34567919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.
    Ito D; Inoue K; Sumita T; Hamaguchi K; Kaneko K; Yanagisawa M; Inukai K; Inoue I; Noda M; Shimada A
    J Clin Med Res; 2018 Sep; 10(9):679-687. PubMed ID: 30116437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
    Okajima F; Nagamine T; Nakamura Y; Hattori N; Sugihara H; Emoto N
    J Diabetes Investig; 2017 May; 8(3):341-345. PubMed ID: 27762088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Maegawa H; Tobe K; Nakamura I; Uno S
    Diabetol Int; 2021 Oct; 12(4):430-444. PubMed ID: 34567926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
    Onishi Y; Ishii H; Oura T; Takeuchi M
    Diabetes Ther; 2020 Mar; 11(3):735-745. PubMed ID: 31994009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.
    Kim HJ; Kim YS; Lee CB; Choi MG; Chang HJ; Kim SK; Yu JM; Kim TH; Lee JH; Ahn KJ; Kim K; Lee KW
    Diabetes Ther; 2019 Aug; 10(4):1271-1282. PubMed ID: 31079357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.